Linker Information

General Information of This Linker
Linker ID
LIN0QVNCR
Linker Name
Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB
Linker Type
Sugar-based site-specific conjugation linker; Cathepsin-cleavable linker
Antibody-Linker Relation
Cleavable
Structure
Formula
C90H132N12O20
Isosmiles
CCC(C)C(C(CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C)C(O)c1ccccc1)OC)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C(=O)OCc1ccc(NC(=O)C(CCCNC(N)=O)NC(=O)C(NC(=O)CCOCCOCCOCCOCCOCCNC(=O)CCC(=O)N2Cc3ccccc3C#Cc3ccccc32)C(C)C)cc1)C(C)C
InChI
InChI=1S/C90H132N12O20/c1-15-61(8)81(73(115-13)55-77(106)101-44-24-32-72(101)83(116-14)62(9)84(108)94-63(10)82(107)67-27-17-16-18-28-67)99(11)88(112)79(59(4)5)98-87(111)80(60(6)7)100(12)90(114)122-57-64-33-37-69(38-34-64)95-85(109)70(30-23-42-93-89(91)113)96-86(110)78(58(2)3)97-75(104)41-45-117-47-49-119-51-53-121-54-52-120-50-48-118-46-43-92-74(103)39-40-76(105)102-56-68-29-20-19-25-65(68)35-36-66-26-21-22-31-71(66)102/h16-22,25-29,31,33-34,37-38,58-63,70,72-73,78-83,107H,15,23-24,30,32,39-57H2,1-14H3,(H,92,103)(H,94,108)(H,95,109)(H,96,110)(H,97,104)(H,98,111)(H3,91,93,113)
InChIKey
WLDJBWZAWMRUNJ-UHFFFAOYSA-N
Pharmaceutical Properties
Molecule Weight
1702.11
Polar area
405.03
Complexity
122
xlogp Value
6.9077
Heavy Count
122
Rot Bonds
53
Hbond acc
20
Hbond Donor
9
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
Trastuzumab-MMAE conjugate DAR12 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) > 10.00 uM Negative HER2 expression (HER2-)
Method Description
The cytotoxicity of the synthetic ADCs were tested in breast cancer cell lines BT474 that have high levels of HER2 expression, and T47D that has low level expression of HER2 antigen.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.04 nM
7.13 ng/mL
High HER2 expression (HER2+++)
Method Description
The cytotoxicity of the synthetic ADCs were tested in breast cancer cell lines BT474 that have high levels of HER2 expression, and T47D that has low level expression of HER2 antigen.
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
Trastuzumab-MMAE conjugate DAR8 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) > 10.00 uM Negative HER2 expression (HER2-)
Method Description
The cytotoxicity of the synthetic ADCs were tested in breast cancer cell lines BT474 that have high levels of HER2 expression, and T47D that has low level expression of HER2 antigen.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.05 nM
8.79 ng/mL
High HER2 expression (HER2+++)
Method Description
The cytotoxicity of the synthetic ADCs were tested in breast cancer cell lines BT474 that have high levels of HER2 expression, and T47D that has low level expression of HER2 antigen.
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
Trastuzumab-MMAE conjugate DAR6 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) > 10.00 uM Negative HER2 expression (HER2-)
Method Description
The cytotoxicity of the synthetic ADCs were tested in breast cancer cell lines BT474 that have high levels of HER2 expression, and T47D that has low level expression of HER2 antigen.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.08 nM
12.68 ng/mL
High HER2 expression (HER2+++)
Method Description
The cytotoxicity of the synthetic ADCs were tested in breast cancer cell lines BT474 that have high levels of HER2 expression, and T47D that has low level expression of HER2 antigen.
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
Trastuzumab-MMAE conjugate DAR4 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) > 10.00 uM Negative HER2 expression (HER2-)
Method Description
The cytotoxicity of the synthetic ADCs were tested in breast cancer cell lines BT474 that have high levels of HER2 expression, and T47D that has low level expression of HER2 antigen.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.10 nM
16.05 ng/mL
High HER2 expression (HER2+++)
Method Description
The cytotoxicity of the synthetic ADCs were tested in breast cancer cell lines BT474 that have high levels of HER2 expression, and T47D that has low level expression of HER2 antigen.
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
Trastuzumab-MMAE conjugate DAR2 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Effective Concentration (EC50) > 10.00 uM Negative HER2 expression (HER2-)
Method Description
The cytotoxicity of the synthetic ADCs were tested in breast cancer cell lines SK-BR-3 and BT474 that have high levels of HER2 expression, and T47D that has low level expression of HER2 antigen.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
Experiment 2 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.07 nM
10.67 ng/mL
High HER2 expression (HER2+++)
Method Description
The cytotoxicity of the synthetic ADCs were tested in breast cancer cell lines SK-BR-3 and BT474 that have high levels of HER2 expression, and T47D that has low level expression of HER2 antigen.
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.41 nM
6.20 ng/mL
High HER2 expression (HER2+++)
Method Description
The cytotoxicity of the synthetic ADCs were tested in breast cancer cell lines SK-BR-3 and BT474 that have high levels of HER2 expression, and T47D that has low level expression of HER2 antigen.
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
References
Ref 1 General and Robust Chemoenzymatic Method for Glycan-Mediated Site-Specific Labeling and Conjugation of Antibodies: Facile Synthesis of Homogeneous Antibody-Drug Conjugates. ACS Chem Biol. 2021 Nov 19;16(11):2502-2514.
Ref 2 Synthesis and Evaluation of Three Azide-Modified Disaccharide Oxazolines as Enzyme Substrates for Single-Step Fc Glycan-Mediated Antibody-Drug Conjugation. Bioconjug Chem. 2022 Jun 15;33(6):1179-1191.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.